DBV Technologies (DBVT) Stock Rating Lowered by BidaskClub
DBV Technologies (NASDAQ:DBVT) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
Other equities research analysts have also recently issued research reports about the company. Deutsche Bank boosted their price target on DBV Technologies from $46.00 to $56.00 in a research note on Sunday, October 8th. Morgan Stanley cut DBV Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, October 23rd. Leerink Swann set a $49.00 price target on DBV Technologies and gave the company an “outperform” rating in a research note on Monday, October 23rd. Societe Generale cut DBV Technologies from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Finally, Barclays lowered their price target on DBV Technologies from $58.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. DBV Technologies presently has a consensus rating of “Hold” and an average price target of $49.63.
Shares of DBV Technologies (DBVT) opened at $25.05 on Thursday. DBV Technologies has a 12 month low of $20.58 and a 12 month high of $50.57.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.